

**AMENDMENTS TO THE CLAIMS**

The following listing of the claims replaces all prior claim listings.

**LISTING OF CLAIMS:**

Claim 1 (Canceled)

Claim 2 (Previously Presented): The method of claim 33, further comprising purifying the Dkk protein by size-exclusion chromatography.

Claim 3 (Previously Presented): The method of claim 33, further comprising treating the culture media with one or more protease inhibitors.

Claim 4 (Previously Presented): The method of claim 33, further comprising the step of filtering the culture media prior to said concentrating.

Claim 5 (Canceled).

Claim 6 (Previously Presented): The method of claim 36, wherein the affinity column is a metal affinity column.

Claim 7 (Previously Presented): The method of claim 2, wherein the size exclusion column is a Superose-12 column, a Superdex-200 column, a Sephadex column, or a Sephadex column.

Claim 8 (Original): The method of claim 6, wherein the metal is nickel, zinc, or iron.

Claims 9-11 (Canceled).

Claim 12 (Currently Amended): The method of ~~claim 9~~ claim 33, further comprising lyophilizing the purified, glycosylated Dkk protein.

Claim 13 (Previously Presented): The method of claim 33, wherein the Dkk protein is Dkk1.

Claim 14 (Original): The method of claim 13, wherein the Dkk1 protein is human Dkk1.

Claim 15 (Previously Presented): The method of claim 3, wherein said treating is performed in the presence of a salt and imidazole.

Claim 16 (Previously Presented): The method of claim 15, wherein the salt is NaCl, LiCl, or KCl, and wherein the salt is in a final concentration of about 100 mM to about 1 M, and the imidazole is present in a final concentration of about 0.5 mM to about 50 mM.

Claim 17 (Original): The method of claim 15, wherein the salt is NaCl and is present at a final concentration of about 500 mM, and the imidazole is present at a final concentration of about 5 mM.

Claim 18 (Previously Presented): The method of claim 6, wherein the metal affinity column is eluted with an imidazole gradient of about 5 to about 1,500 mM imidazole, and wherein the Dkk protein is tagged with histidine.

Claim 19 (Previously Presented): The method of claim 18, wherein the imidazole gradient is about a 20 mM to about a 1,000 mM imidazole.

Claim 20 (Previously Presented): The method of claim 18, wherein the Dkk protein is human Dkk1, and the metal affinity column is a nickel affinity column.

Attorney Docket No.: 47038-0247-00-US (227744)

Application No.: 10/593,089

Reply to Office Action mailed: May 25, 2010

Reply dated: August 13, 2010

Page 4

Claim 21 (Previously Presented): The method of claim 33, wherein the mammalian host cell is a HEK293T or HEK293 EPNA cell.

Claims 22-32 (Canceled)

Claim 33 (Currently Amended): A method of concentrating an active, glycosylated Dkk protein, comprising:

concentrating a culture media containing an active, glycosylated Dkk protein in the presence of EDTA and a detergent to obtain a concentrated Dkk protein,

wherein the detergent does not inhibit the activity of the Dkk protein, [[and]]

wherein a mammalian host cell expresses the Dkk protein and secretes the Dkk protein into the culture media, and

wherein the detergent is Tween-20 in the amount of about 0.01% to about 1% Tween-20,  
and EDTA is present in the amount of about 0.01 mM to about 2 mM EDTA.

Claim 34 (Previously Presented): The method of claim 33, wherein the yield of Dkk protein from the culture media is at least about 80%.

Claim 35 (Previously Presented): The method of claim 33, wherein the concentration of the active, glycosylated Dkk protein is at least about 2 mg/mL.

Claim 36 (Previously Presented): The method of claim 33, further comprising purifying the culture media across an affinity column prior to said concentrating.